Wu, W.

Yale University

Unclaimed · AI-structured profileORCID OpenAlex

Yale researcher spanning translational lung cancer biology and brain-gut clinical research in pain medicine

papers here

reviewed by Evolve

first-author

corresponding

—

works · OpenAlex

—

h-index · OpenAlex

Bibliometric figures come from OpenAlex (2026-10-02) and cover the author's entire public record, not just the papers listed here. Reproducibility signal comes from Evolve's own reviews.

Research profile

Output—

No output score yet: this snapshot lacks the publication-count data the axis requires. Output would measure the volume of the researcher's papers over time, including preprints and peer-reviewed articles.

Impact—

No impact score yet: citation counts and influence metrics are absent from the snapshot. Impact would measure how frequently and how widely the research community cites and builds on this researcher's work.

Focus0/100

The focus score is 0, grounded in the raw field distribution: 0.5 cancer biology / translational oncology and 0.5 pain medicine (brain-gut axis clinical research). The two cataloged 2026 papers sit in these separate domains — an EGFR-resistance mechanism study and an IBS pain-intervention protocol — so activity is evenly divided rather than concentrated, and no single field yet dominates this early-stage profile.

Collaboration66/100

Collaboration scores 66, derived from 27 distinct coauthors across the reviewed work. The recurring-collaborator list is long and stable — Gini, B., Gui, P., Kerr, D. L., Tan, L., Barbosa, D., Olivas, V., Allegakoen, P., Gomez, C., Halliday, P., Elmes, S., Steri, V., and Chakrabarti, T. — consistent with team-based biomedical science. Authorship roles vary: middle author on the oncology study, first and corresponding on the clinical protocol.

Activity—

No activity score yet: year-by-year publication cadence cannot be computed from only two 2026 records. Activity would measure ongoing research output and engagement across recent years.

Reproducibility38/100

Reproducibility averages 38 (reproMean) across 2 papers with assessments (reproPapers = 2). The CDK4/6 lung cancer study is rated medium: Evolve credits convincing model triangulation but flags underpowered sequencing arms. The IBS music-intervention paper is rated low: it is a protocol-only, single-arm pilot (N = 36) with rich multimodal measures but no control arm. Both ratings constrain how readily the work can be independently replicated.

Research summary

Wu, W. is a researcher at Yale University whose Evolve-reviewed work to date splits evenly between two domains: cancer biology / translational oncology and pain medicine centered on the brain-gut axis (field distribution 0.5 / 0.5). In oncology, Wu contributed as a middle author to a 2026 bioRxiv study proposing that upregulation of CDK4 or CDK6 induces DNA replication stress and genomic instability, driving resistance to EGFR-targeted therapy in EGFR-mutant lung cancer; Evolve's review found the model triangulation convincing while flagging underpowered sequencing arms. In pain medicine, Wu is first and corresponding author of a 2026 medRxiv protocol for a single-arm pilot study testing a 4-week monochord music-based intervention for abdominal pain in adults with irritable bowel syndrome (N = 36), with rich multimodal measures including wearable biosensors — though the design lacks a control arm. The reviewed network spans 27 distinct coauthors (collaboration score 66), with frequent collaborators including Gini, B., Gui, P., Kerr, D. L., and Tan, L. Reproducibility averages 38 across the 2 assessed papers (medium readiness for the lung cancer study, low for the protocol-only pilot). Output, impact, and activity cannot yet be scored: citation and longitudinal productivity data are insufficient in the current snapshot, making this an early-stage profile.

Collaboration pattern

Wu's reviewed work spans 27 distinct coauthors (collaboration score 66), a pattern typical of team-based biomedical research. Recurring collaborators include Gini, B., Gui, P., Kerr, D. L., Tan, L., Barbosa, D., Olivas, V., Allegakoen, P., Gomez, C., Halliday, P., Elmes, S., Steri, V., and Chakrabarti, T. The role shifts by project: a contributing middle author on the lung cancer genomics study, but first and corresponding author leading the IBS music-intervention pilot protocol.

Research keywords

EGFR-mutant lung adenocarcinomaCDK4/6 amplificationOsimertinib resistanceReplication stressGenomic instabilityFraction of genome alteredIrritable bowel syndromeMusic-based interventionMusic therapyAbdominal painBrain-gut axisWearable biosensors

Highlights

CDK4/6 upregulation implicated in EGFR targeted-therapy resistance
On a 2026 bioRxiv study (middle author), Wu contributed to evidence that CDK4 or CDK6 upregulation induces DNA replication stress and genomic instability driving EGFR-TKI resistance in EGFR-mutant lung cancer. Evolve judged the model triangulation convincing though the sequencing arms are underpowered; reproducibility readiness: medium.
First/corresponding authorship of a music-based IBS pain pilot protocol
Wu leads a 2026 medRxiv protocol (first and corresponding author) for a single-arm pilot (N = 36) of a 4-week monochord music intervention for abdominal pain in adults with irritable bowel syndrome, with rich multimodal measures including wearable biosensors. Evolve calls it rigorously specified but notes the absence of any control arm; reproducibility readiness: low.
An even two-field split across mechanism and clinical research
The raw field distribution is 0.5 cancer biology / translational oncology and 0.5 pain medicine (brain-gut axis), and the resulting focus score of 0 reflects this breadth. Both cataloged works appeared in 2026, pairing genomic-instability mechanisms with multimodal clinical measurement.

Timeline

2026Co-authored (middle position) the bioRxiv study proposing CDK4/6-driven replication stress and genomic instability as the basis of EGFR targeted-therapy resistance in lung cancer.
2026Published the medRxiv protocol as first and corresponding author: a single-arm pilot (N = 36) of 4-week monochord music for irritable bowel syndrome pain.
2026Both cataloged preprints land in the same year, splitting the profile evenly between translational oncology and brain-gut pain medicine.

Papers in the Evolve catalog

Frequent co-authors

Gini, B.×1 Gui, P.×1 Kerr, D. L.×1 Tan, L.×1 Barbosa, D.×1 Olivas, V.×1 Allegakoen, P.×1 Gomez, C.×1 Halliday, P.×1 Elmes, S.×1 Steri, V.×1 Chakrabarti, T.×1

About this profile

This profile is AI-structured by Evolve.Pub from public bibliographic data (OpenAlex) and Evolve's own paper reviews. It is not written or endorsed by the researcher unless the profile is claimed. Radar dimensions are computed from real bibliometrics with fixed formulas — raw figures are shown alongside; missing dimensions mean insufficient data, never zero. Errors? Claim the profile to correct or hide it.

Dimension scores come from a limited bibliometric snapshot; only collaboration (66), focus (0), and reproducibility (38) could be computed.
Output, impact, and activity axes lack underlying data (publication counts, citations, longitudinal cadence) and are intentionally left unscored.
The Evolve catalog includes only 2 papers for this researcher, both 2026 preprints (bioRxiv / medRxiv); peer-reviewed publication status and citation history are not reflected.
'Wu, W.' is a common name; this profile is resolved from public bibliographic data linked to ORCID 0000-0002-1885-7198 and may not capture the researcher's full record.